Premium
Serial haemostatic monitoring of dogs with multicentric lymphoma
Author(s) -
Kol A.,
Marks S. L.,
Skorupski K. A.,
Kass P. H.,
Guerrero T.,
Gosselin R. C.,
Borjesson D. L.
Publication year - 2015
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12041
Subject(s) - medicine , thromboelastography , canine lymphoma , lymphoma , hematology , chemotherapy , gastroenterology , malignancy , surgery , coagulation
Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin–antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty‐seven dogs were included in the study and 15 completed the study in remission. At presentation, 81% (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4 weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.